Drug Landscape ›
Glimepiride 2 mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 22
Most-reported reactions
Blood Glucose Increased — 4 reports (18.18%) Product Quality Issue — 4 reports (18.18%) Drug Ineffective — 3 reports (13.64%) Death — 2 reports (9.09%) Nausea — 2 reports (9.09%) Pruritus — 2 reports (9.09%) Rash Erythematous — 2 reports (9.09%) Adverse Drug Reaction — 1 report (4.55%) Angioedema — 1 report (4.55%) Blood Glucose Decreased — 1 report (4.55%)
Source database →
Glimepiride 2 mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Glimepiride 2 mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Glimepiride 2 mg in United States?
Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.